Evidence map›Paper›PMID 35745561›Full record

ArticlePathogens (Basel, Switzerland)2022

Aspartyl Protease Inhibitors as Anti-Filarial Drugs.

Liana Beld, Hyeim Jung, Christina A Bulman, Bruce A Rosa, Peter U Fischer, James W Janetka, Sara Lustigman, Judy A Sakanari, Makedonka Mitreva

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Anti-filarial efficacy ofRSC advances · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Liana BeldDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.
Hyeim JungDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-1083-2882
Christina A BulmanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.
Bruce A RosaDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0002-6820-446X
Peter U FischerDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0003-4558-3417
James W JanetkaDepartment of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St. Louis, MO 63110, USA.
Sara LustigmanMolecular Parasitology, New York Blood Center, Lindsley F. Kimball Research Institute, New York, NY 10065, USA.ORCID 0000-0003-2389-6113
Judy A SakanariDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.
Makedonka MitrevaDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.ORCID 0000-0001-9572-3436
Washington University in St. Louis · USUniversity of California, San Francisco · USJames S. McDonnell Foundation · USNew York Blood Center · US

Funding

Development of small molecule inhibitors of metabolic enzymes as broad spectrum anthelmintic drugsR01AI159450 · NIAID · WASHINGTON UNIVERSITY · PI JANETKA, JAMES W, MITREVA, MAKEDONKA · 2021 to 2025
$3.9M
National Institute of Allergy and Infectious Diseases 1R01AI159450NIAID NIH HHS R01 AI159450
6 · The paper itself

Abstract

The current treatments for lymphatic filariasis and onchocerciasis do not effectively kill the adult parasitic nematodes, allowing these chronic and debilitating diseases to persist in millions of people. Thus, the discovery of new drugs with macrofilaricidal potential to treat these filarial diseases is critical. To facilitate this need, we first investigated the effects of three aspartyl protease inhibitors (APIs) that are FDA-approved as HIV antiretroviral drugs on the adult filarial nematode,

Indexed as

anti-filarial drugsfilarial nematodesgastro-intestinal nematodesmacrofilaricidalNeglected tropical diseases (NTDs)Trichuris

Identifiers

PMID35745561
PMCPMC9227574
OpenAlexW4283171956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.